Document is current

Article History

Received: 3 April 2020

Accepted: 14 September 2020

First Online: 6 October 2020

Ethics approval and consent to participate

: This study was an institutionally approved by Saitama Medical University. All procedures will be performed in accordance with the ethical standards of the institutional and/or national research committee and with the 2013 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants in our study. This study has been registered in the Japan Registry of Clinical Trials (JRCT) (jRCTs031190070).

: Not applicable.

: K. Kaira has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan and AstraZeneca. AM has received a speaker honorarium from Eli Lilly, Taiho Pharmaceutical, Pfizer, Chugai Pharmaceutical and AstraZeneca. KY has received a speaker honorarium from AstraZeneca. HK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Bristol-Myers Company, Boehringer Ingelheim, MSD, Daiichi Sankyo Company, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck Biopharma Company, Eli Lilly Japan and AstraZeneca. K. Kobayashi has received research grants and a speaker honorarium from Boehringer Ingelheim, AstraZeneca and Bristol-Myers Company. SK has no conflicts of interest.